推荐产品
质量水平
方案
≥98% (HPLC)
颜色
white
溶解性
H2O: soluble 12 mg/mL at 60 °C
创始人
Promius
SMILES字符串
Cl.NC(=N)NC(=O)Cc1c(Cl)cccc1Cl
InChI
1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
InChI key
DGFYECXYGUIODH-UHFFFAOYSA-N
基因信息
human ... ADRA2A(150) , ADRA2B(151) , ADRA2C(152)
正在寻找类似产品? 访问 产品对比指南
应用
Guanfacine hydrochloride has been used as an α2A adrenoceptor agonist to test its protective effect on hypobaric hypoxia (HH) and in rat brain to measure blood oxygenation level dependent (BOLD) response.
生化/生理作用
Guanfacine stimulates the brain postsynaptic α2 adrenergic receptor (AR) and mediates the prefrontal cortical (PFC) neuronal regulation and strengthens their network. Guanfacine improves the density of neuronal dendrites and is useful in treating neuropsychiatric disorders. It modulates the synaptic and cytoskeletal proteins expression in prefrontal cortical (PFC) neurons and may improve hypobaric hypoxia (HH) induced PFC dysfunctions. Guanfacine enhances cognitive function and is recommended for attention deficit hyperactivity disorder (ADHD) therapy.
α-2 noradrenergic receptor agonist.
特点和优势
This compound was developed by Promius. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
Yuanyuan Li et al.
Bioanalysis, 4(12), 1445-1456 (2012-07-17)
Direct analysis of dried blood spot (DBS) samples was investigated using a prototype semi-automated robotic device that allows the direct elution of sample spots from a DBS paper card to an online SPE cartridge. The eluted SPE samples were analyzed
Once-daily treatment of ADHD with guanfacine: patient implications
Strange BC
Neuropsychiatric Disease and Treatment, 4(3), 499-499 (2008)
Guanfacine promotes neuronal survival in medial prefrontal cortex under hypobaric hypoxia
Kauser H, et al.
Brain Research, 1636, 152-160 (2016)
Timothy E Wilens et al.
Journal of the American Academy of Child and Adolescent Psychiatry, 51(1), 74-85 (2011-12-20)
To examine efficacy, tolerability, and safety of guanfacine extended release (GXR; ≤4 mg/d) adjunctive to a long-acting psychostimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years of age with suboptimal, but partial, response
Jean Lachaine et al.
Postgraduate medicine, 124(3), 139-148 (2012-06-14)
To understand attention-deficit/hyperactivity disorder (ADHD) treatment patterns and estimate adherence and persistence in Quebec, Canada. This cross-sectional, retrospective prescription claims analysis used a random sample of 15 838 patients with ADHD from a Quebec database (Régie de l'assurance maladie du
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门